|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0026882,
umls-concept:C0205210,
umls-concept:C0205263,
umls-concept:C0346153,
umls-concept:C0376571,
umls-concept:C0439849,
umls-concept:C0445223,
umls-concept:C0449438,
umls-concept:C0871261,
umls-concept:C1522449,
umls-concept:C1552599,
umls-concept:C1704632,
umls-concept:C1704787,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-11-13
|
|
pubmed:abstractText |
BRCA1/2 germline mutations are associated with impaired DNA double-strand break repair. We tested whether breast cancers in BRCA1/2 mutation carriers were more responsive to induction treatments than in noncarriers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
127-31
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19307946-Aged,
pubmed-meshheading:19307946-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19307946-Apoptosis Regulatory Proteins,
pubmed-meshheading:19307946-BRCA1 Protein,
pubmed-meshheading:19307946-BRCA2 Protein,
pubmed-meshheading:19307946-Breast Neoplasms,
pubmed-meshheading:19307946-Chemotherapy, Adjuvant,
pubmed-meshheading:19307946-Combined Modality Therapy,
pubmed-meshheading:19307946-Female,
pubmed-meshheading:19307946-Germ-Line Mutation,
pubmed-meshheading:19307946-Humans,
pubmed-meshheading:19307946-Middle Aged,
pubmed-meshheading:19307946-Neoadjuvant Therapy,
pubmed-meshheading:19307946-Neoplasm Staging,
pubmed-meshheading:19307946-Prognosis,
pubmed-meshheading:19307946-Radiotherapy,
pubmed-meshheading:19307946-Retrospective Studies,
pubmed-meshheading:19307946-Survival Rate
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
|
|
pubmed:affiliation |
Departments of Radiation Oncology, Institut Curie, Paris, France. alain.fourquet@curie.net
|
|
pubmed:publicationType |
Journal Article
|
